Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Vertex Pharmaceuticals Incorporated (VRTX): Hal Mintz, David Shaw, and Phill Gross Are Big Winners

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is up more than 42% after reporting successful results of its cystic fibrosis treatment. Tech Insider yesterday published an article about a CNBC report and pointed out the potential large gains in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Here is an excerpt from that article:

The first drug to treat this disease is kalydeco which restores the ability of the protein to let chloride pass through cells. However, only 2,000 people with cystic fibrosis can be treated by kalydeco based on their particular gene mutations. Another problem posed by the disease is that the proteins cannot even reach the membrane. This is where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) comes in with a new drug called lumacaftor which will aid in this particular problem. After this problem is eliminated, drugs such as kalydeco are expected to work. It is estimated that up to 28,000 patients can be helped by this combination.

Tirrell pointed out that this expanded market means bigger business for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Positive data regarding this combination of drugs to treat cystic fibrosis will drive the stock, she added. Currently trading at about $67, analysts say that positive data will likely drive the stock over $100 while negative data will likely plunge it into the $40s.

David E. Shaw Vertex Pharmaceutical

Even though several hedge funds had large positions in Vertex, the stock isn’t one of the popular biotech stocks. There were only 26 hedge funds (out of the 650 that we are tracking) with bullish VRTX positions at the end of the first quarter. Hal Mintz’s Sabby Capital was the biggest hedge fund winner of the day. The fund held call options, which may subsequently converted into stock positions, worth nearly $170 million. David Shaw’s D. E. Shaw boosted its stake by 163% during the first quarter and held $134 million worth of common shares. Their one day gain is around $50 million assuming that they haven’t reduced their position in the stock. Phill Gross’ Adage Capital had $117 million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) at the end of the first quarter. Other notable investors in the stock are Israel Englander, Joseph Edelman, and Steven Cohen.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!